



Keeping Specialty Medications in our Community Pharmacies

News Release

FOR IMMEDIATE RELEASE

October 6, 2011

Contact: Gerry Crocker, CEO

866-907-2776

CSPN is happy to announce that we have entered into a distribution agreement with Access Pharmaceuticals for its oral mucositis product, MuGard. CSPN will now be an integral member of the MuGard hub which will mean a significant amount of referrals for this product will pass to our membership.

MuGard is a viscous, mucoadhesive rinse which provides a protective coating to the oral mucosa. MuGard is designed to form a protective hydrogel coating over the oral mucosa while a patient is undergoing chemotherapy and/or radiotherapy cancer treatments to the head and neck. MuGard has been shown to reduce and delay the onset of oral mucositis, a debilitating side effect of anticancer regimens.

Anthony Mottola, VP Managed Care and Market Access, Access Pharmaceuticals, Inc. stated, "We are pleased to team up with CSPN to further broaden our market access strategy which combines various Pharmacy Benefit Managers (PBM's), like CVS Caremark and Express Scripts, large payers like Humana and United Healthcare along with additional networks of specialty pharmacies, such as CSPN. By leveraging CSPN's distribution network, we are able to offer added patient and provider support services, through our full-service HUB, the MuGard Patient Reimbursement and Support Center (MuGard PRSC).

Nick Calla, Vice President of Industry Relations, stated "This program has put us in a great position to gain a large number of referrals for this product. We are only one of two specialty pharmacy entities in the referral program for Access at this time."

CSPN in partnership with Access Pharmaceuticals have been successful in getting recognition for our community based model and the value it can provide through our high touch model of patient care. In partnership with the full-service HUB, the MuGard Patient Reimbursement and Support Center (MuGard PRSC), these patients will have many avenues of support available to them.

MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of [oral mucositis](#), a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of \$1 billion world-wide. For more information, please visit www.MuGard.com.

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include [MuGard™](#) (www.MuGard.com).

CSPN is the largest community specialty network in the country with over 190 member pharmacies operating in 44 states servicing over 45,000 specialty lives. With over \$2.2 Billion in total Rx purchases and \$600 Million in Specialty Rx, CSPN is now the nation's 10th largest specialty provider. CSPN and its network provide a unique distribution channel which allows immediate availability of critically required specialty medication. It is delivered by a compassionate, highly competent staff of pharmacy professionals dedicated to improving patients' lives. For more information about CSPN, visit www.cspnrx.com.

401 Pilgrim Lane, Suite 201, Drexel Hill PA 19026

(p) 1.866.907.2776 / (f) 610.449.3405